PFE · News · 20260922N

Product Launch and Transition

PFIZER INC · 2026-09-22 · Importance 68 · Surprise 58

New and acquired products accounted for 21.2% of Pfizer’s revenue and were growing 18% year over year. Pfizer is emphasizing cancer, vaccines, and obesity treatments as core areas for portfolio renewal and post-COVID growth. Metsera candidates were described as matching or outperforming some leading GLP-1 therapies, with potential to support growth from 2028 onward. New product sales are increasing particularly in international markets, helping offset declining COVID demand.